Thus, MPL mutations revealed fewer modifications than those with JAK2 and CALR mutations, and this was also observed when we excluded the two ET samples with MPL mutation (882 hyper- and 598 hypomethylated CpGs). The gene discussed is JAK2; the disease is essential thrombocythemia.